Dermatomyositis/polymyositis and anti-TNF-α therapies: a literature review

Brunasso, Alexandra Mg; Aberer, Werner; Massone, Cesare

doi:10.1586/17469872.2013.836923

Cited by 10 publications

(21 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most prevalent BAs used in patients with BA‐induced AIBD were anti‐TNF‐α therapies. Anti‐TNF‐α agents have been associated with the development of cutaneous immune‐related adverse effects such as new‐onset or worsening of psoriasis, vasculitis, lupus‐like syndrome, Stevens‐Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, sarcoidosis, and dermatomyositis, while rarely associated with BP, PV, or LABD. Paradoxically, anti‐TNF‐α agents have been reported to be efficacious in the treatment of AIBD, though this has only been supported by small cases, with a lack of response in larger studies …”

Section: Discussionmentioning

confidence: 99%

Autoimmune blistering diseases provoked during the treatment of chronic inflammatory disease with biologic agents: a systematic review

Gibson

Amber

2019

Int J Dermatology

View full text Add to dashboard Cite

Background To investigate the clinical course of autoimmune blistering diseases (AIBDs) following treatment with biologic agents (BAs) for chronic inflammatory diseases.Methods A comprehensive review of available, published literature was performed using PubMed and CINAHL search engines. Diagnostic criteria of AIBD included positive direct immunofluorescence studies and/or positive serology with clinically suggestive features.Results A total of 22 cases of AIBDs provoked by the use of BAs were found. The most commonly implicated agents were tumor necrosis factor-alpha inhibitors (n = 14). The mean age of onset of AIBD was 59.4 years (median 61.5 years, range 31-82). Average time to onset of AIBD following initiation of the suspected BA was 33.7 AE 43.8 weeks (range 3 days to 152 weeks). Psoriasis was the most common associated condition for which the BA was prescribed (n = 11), followed by rheumatoid arthritis (n = 6) and ulcerative colitis (n = 5). Of the 21 cases reporting AIBD outcome, 17 reported remission or complete resolution upon stopping treatment with the involved BA. Four cases reported continued bullae formation without worsening of disease following cessation of the BA or systemic corticosteroids used to treat the AIBD. Five cases rechallenged the patient with the involved BA and four of the five reported recurrence, often with quicker onset and more severe symptoms.Conclusions BAs may be suspected in patients developing AIBD while being treated for chronic inflammatory diseases. A majority of cases resolve upon cessation of the offending agent.

show abstract

Section: Discussionmentioning

confidence: 99%

Autoimmune blistering diseases provoked during the treatment of chronic inflammatory disease with biologic agents: a systematic review

Gibson

Amber

2019

Int J Dermatology

View full text Add to dashboard Cite

show abstract

“…In der Literatur sind 20 Fälle von TNF-Inhibitor-induzierten inflammatorischen Myopathien beschrieben [5], wobei es sich hierbei vorwiegend um RA-Patienten mit Nachweis von ANA handelt. Ähnlich wie bei den anderen beschriebenen Autoimmunopathien war es auch bei den myositischen Manifestationen nach Beendigung bzw.…”

Section: Inflammatorische Myopathienunclassified

“…Bei 30 % der Patienten dieser Serie waren anti-Synthetase-Antikörper nachweisbar mit zum Teil zusätzlicher Manifestation einer interstitiellen Lungenerkrankung [5]. Auch hier bleibt die Frage offen, ob es sich bei einem Teil der Fälle nicht möglicherweise um präexistente Overlap-Phänomene (auch im Sinne eines klassischen Jo1-bzw.…”

Section: Inflammatorische Myopathienunclassified

Seltene Nebenwirkungen von biologischen DMARD

Nigg¹,

Feuchtenberger²

2019

Arthritis und Rheuma

View full text Add to dashboard Cite

ZusammenfassungDie Einführung der Biologika Ende der 1990er-Jahre hat zweifelsohne die Behandlungsmöglichkeiten entzündlich rheumatischer Systemerkrankung nachhaltig verändert, um nicht zu sagen revolutioniert. Zusammen mit der Etablierung von Konzepten zur frühen Diagnose und therapeutischen Intervention sowie Treat-to-Target-Strategien mit dem Ziel der Remission hat sich die Prognose rheumatologischer Patienten erheblich verbessert. Nach nunmehr bis zu 20-jähriger Anwendung in der klinischen Routine kann zudem von einer überwiegend guten Verträglichkeit und Sicherheitsdatenlage der Biologika ausgegangen werden. Dennoch finden sich mitunter seltene unerwünschte Arzneimittelwirkungen. Dieser Artikel beschäftigt sich genau mit den eher selteneren unerwünschten Arzneimittelwirkungen, welche in der klinischen Routine dennoch berücksichtigt werden müssen.

show abstract

“…How TNF blockade causes worsening inflammation in inflammatory conditions is poorly understood. Adding to the complexity of this story, 20 cases of DM or PM have been reported after induction of anti-TNF treatment for other autoimmune diseases [12].…”

Section: Neuromuscular Disease Autoimmune Inflammatory Myopathiesmentioning

confidence: 99%

Cytokine Therapies in Neurological Disease

Azodi

Jacobson

2016

Neurotherapeutics

View full text Add to dashboard Cite

Cytokines are a heterogeneous group of glycoproteins that coordinate physiological functions. Cytokine deregulation is observed in many neurological diseases. This article reviews current research focused on human clinical trials of cytokine and anticytokine therapies in the treatment of several neurological disease including stroke, neuromuscular diseases, neuroinfectious diseases, demyelinating diseases, and neurobehavioral diseases. This research suggests that cytokine therapy applications may play an important role in offering new strategies for disease modulation and treatment. Further, this research provides insights into the causal link between cytokine deregulation and neurological diseases.

show abstract

Dermatomyositis/polymyositis and anti-TNF-α therapies: a literature review

Cited by 10 publications

References 52 publications

Autoimmune blistering diseases provoked during the treatment of chronic inflammatory disease with biologic agents: a systematic review

Autoimmune blistering diseases provoked during the treatment of chronic inflammatory disease with biologic agents: a systematic review

Seltene Nebenwirkungen von biologischen DMARD

Cytokine Therapies in Neurological Disease

Contact Info

Product

Resources

About